Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2369
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism ; volume:17 ; number:1 ; day:15 ; month:11 ; year:2016 ; pages:1-7 ; date:12.2016
BMC nephrology ; 17, Heft 1 (15.11.2016), 1-7, 12.2016
- Keyword
-
Bewegungsapparat
Haut
- Creator
-
Kuczera, Piotr
- Contributor
-
Adamczak, Marcin
Więcek, Andrzej
SpringerLink (Online service)
- DOI
-
10.1186/s12882-016-0392-6
- URN
-
urn:nbn:de:1111-20170316687
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kuczera, Piotr
- Adamczak, Marcin
- Więcek, Andrzej
- SpringerLink (Online service)
Other Objects (12)
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Serum sclerostin is an independent predictor of mortality in hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing maintenance hemodialysis
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
Recurrence hyperparathyroidism caused by synchronous parathyroid carcinoma and parathyromatosis in a patient with long-term hemodialysis
Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study
Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Serum sclerostin is an independent predictor of mortality in hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing maintenance hemodialysis
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
Recurrence hyperparathyroidism caused by synchronous parathyroid carcinoma and parathyromatosis in a patient with long-term hemodialysis
Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study
Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Serum sclerostin is an independent predictor of mortality in hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing maintenance hemodialysis
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
Recurrence hyperparathyroidism caused by synchronous parathyroid carcinoma and parathyromatosis in a patient with long-term hemodialysis
Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study
Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients